Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aflibercept

            Therapeutic Area: Ophthalmology Product Name: OT-702

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shandong Boan Biological Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 30, 2020

            Details:

            Ocumension has been granted the exclusive right to promote and commercialize OT-702 in China. OT-702 is in phase III clinical trial and is the company's third line product to enter phase III in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NCX 470

            Therapeutic Area: Ophthalmology Product Name: OT-301

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nicox SA

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Nicox and Ocumension will jointly fund the second NCX 470 Phase 3 glaucoma trial, Denali, which is expected to start by end of 2020 and will also evaluate NCX 470 ophthalmic solution, 0.1%, versus latanoprost ophthalmic solution, 0.005%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bevacizumab

            Therapeutic Area: Ophthalmology Product Name: HLX04

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Henlius

            Deal Size: $25.0 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement October 15, 2020

            Details:

            Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).